Abstract
The correct diagnosis methods of Renal Cell Carcinoma (RCC) with Xp11.2 translocations are controversial in the current literature. Due to the possible failures of immunohistochemistry alone. So we present a possible scientific based answer with the articles yet available.
Highlights
Renal cell carcinoma (RCC) with Xp11.2 translocations was delineated as a distinct entity in 2004 by the World Health Organization
transcription factor E3 (TFE3) translocation renal cell carcinoma is an aggressive tumor with overall survival similar to that of clear cell renal cell carcinoma [4,6,7]
It’s known that Xp11 translocation renal cell carcinoma is cytogenetically characterized by chromosomal translocations involving breakpoints in the TFE3 gene, which maps to the Xp11.2 locus
Summary
Renal cell carcinoma (RCC) with Xp11.2 translocations was delineated as a distinct entity in 2004 by the World Health Organization. It’s known that its morphology and clinical manifestations normally overlap with those of conventional RCCs [1]. The exact incidence of TFE3 translocation renal cell carcinoma among adults remains debatable but estimates range from 1 to 4% of all renal cell carcinoma, with approximately 2500 new cases diagnosed every year [3,4,5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
